Skip Navigation

European Heart Journal 1990 11(2):149-155;
Copyright © 1990 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by EMMERICH, J.
Right arrow Articles by ROUFFY, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by EMMERICH, J.
Right arrow Articles by ROUFFY, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 The European Society of Cardiology

Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia

J. EMMERICH*,, I. AUBERT{dagger}, B. BAUDUCEAU{ddagger}, A. DACHET*, B. CHANU{dagger}, D. ERLICH{dagger}, D. GAUTHIER{dagger}, B. JACOTOT{ddagger} and J. ROUFFY{dagger}

*Unité de recherches sur les dyslipidémies et l'atherosclérose, INSERM U32, Hô pital Henri Mondor Creteil
{dagger}Service de medecine Interne et Pathologie vasculire, Ho{diaeresis}pital Saint Louis
{ddagger}Service D'Edocrinolopgie., Hôspital D'Instruction des Armées Bégin Saint Made, France

Received 2 May 1989; revised 26 May 1989; .

Correspondence: J. Emmerich, Unité de recherches sur les dyslipidémies et I'atherosclérose, INSERM U 32, Hôpital Henri Mondor, 94010 Creteil Cedex, France.

Abstract

The effects and safety of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, were investigated alone or in association with cholestyramine in 66 patients with hypercholesterolaemia, in a 1-year study. In type Ha hypercholesterolaemia (41 patients), the association was more effective than simvastatin used alone in lowering total cholesterol (37% vs 29%) and LDL-cholesterol (45% vs 37%). In type lib hypercholesterolaemia (23 patients), the association simvastatin-cholestyramine did not appear more effective than simvastatin used alone. The decrease of apoprotein B was parallel to the LDL-cholesterol decrease. Apoprotein A1 did not change significantly. The long-term safety of simvastatin was good. No lens opacity was noted. The most serious side-effect in our study was myolysis which occurred in two patients with a marked increase in creatine phosphokinase.

Key Words: Hydroxymethylglutaryl coenzyme A reductase • simvastatin • serum lipids • apoprotein • chlolestyramine • familial hypercholesterolaemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
D. M. Black, R. G. Bakker-Arkema, and J. W. Nawrocki
An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor
Arch Intern Med, March 23, 1998; 158(6): 577 - 584.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.